0969-8051
Bimonthly
No
NUCL MED BIOL
1993
94
UNITED STATES
http://www.journals.elsevier.com/nuclear-medicine-and-biology/
一般,3-8周审稿时间
容易平均录用比例
3.0影响因子
核医学小学科
59/212JIF RANK
3180总被引频次
月期刊平台服务过的文章录用时间为1-3个月,依据20年经验,经月期刊专家预审通过后的文章,投稿通过率100%以上!
核医学和生物学旨在为描述原始合成、体外组织研究或体内使用放射性示踪剂、放射性药物或治疗剂的原始研究贡献。论文集中于合成、体外试验和体内化合物的检测。广泛的研究证明了在体内定位的机制,无论是基于受体,酶,或肿瘤抗原结合或其他明确定义的过程是每一个评估的一个组成部分。此外,研究应确定一个重要的化合物,是一个敏感的探针的生化变化在体内。
http://ees.elsevier.com/nucmedbio/default.asp?pg=preRegistration.asp
Nuclear Medicine and Biology is intended for original research contributions describing original synthesis, in vitro tissue studies, or in vivo use of radiotracers, radiopharmaceuticals, or therapeutic agents. Papers concentrate on the synthesis, testing in vitro, and examination of a compound in vivo. Extensive studies proving the mechanism of localization in vivo whether the radioactive substance is based on receptor-, enzyme-, or tumor antigen-binding or other well defined processes are an integral part of each evaluation. Additionally, studies should define a significant compound that is a sensitive probe of a biochemical change in vivo.